Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 4/20 | 0.49 |
| ▸ | APP | P05067 | 1/20 | 0.49 |
| ▸ | MMP2 | P08253 | 4/20 | 0.48 |
| ▸ | MMP9 | P14780 | 3/20 | 0.48 |
| ▸ | MMP13 | P45452 | 3/20 | 0.48 |
| ▸ | MMP8 | P22894 | 2/20 | 0.48 |
| ▸ | BCHE | P06276 | 1/20 | 0.47 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.45 |
| ▸ | TXNRD3 | Q86VQ6 | 1/20 | 0.45 |
| ▸ | TXNRD2 | Q9NNW7 | 1/20 | 0.45 |
| ▸ | NFE2L2 | Q16236 | 3/20 | 0.44 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | TLR2 | O60603 | 1/20 | 0.44 |
| ▸ | ERN1 | O75460 | 1/20 | 0.44 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.44 |
| ▸ | TLR6 | Q9Y2C9 | 1/20 | 0.44 |
| ▸ | ABL1 | P00519 | 1/20 | 0.43 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2123263 | 0.91 | BACE1 (0.57) | BACE1MAPTAPPMMP2MMP9 | |
| SCHEMBL10077701 | 0.87 | PTGER4 (0.47) | BACE1MAPTAPPMMP2MMP9 | |
| SCHEMBL19960660 | 0.84 | BACE1 (0.54) | BACE1MAPTAPPMMP2MMP9 | |
| SCHEMBL7724020 | 0.76 | BACE1 (0.82) | BACE1MAPTAPPBCHETXNRD1 | |
| SCHEMBL7724027 | 0.76 | BACE1 (0.82) | BACE1MAPTAPPBCHETXNRD1 | |
| SCHEMBL16558605 | 0.73 | MMP2 (0.60) | MMP2MMP9MMP13MMP8NFE2L2 | |
| SCHEMBL2124592 | 0.72 | MMP2 (0.59) | MAPTMMP2MMP9MMP13MMP8 | |
| SCHEMBL3687130 | 0.72 | KDM4E (0.66) | BACE1MAPTAPPBCHETXNRD1 | |
| SCHEMBL3687134 | 0.72 | KDM4E (0.66) | BACE1MAPTAPPBCHETXNRD1 | |
| SCHEMBL11260285 | 0.72 | KDM4E (0.73) | BACE1MAPTAPPBCHETXNRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9675576-B2 | Polyenolic zinc-binding agents (pezbins) actively promote inactivation of cancer stem cells and potentiate cytotoxic anti-tumor drug substances | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2017-06-13 | — | — | US | disclosed |
| US-20160213638-A1 | POLYENOLIC ZINC-BINDING AGENTS (PEZBINS) ACTIVELY PROMOTE INACTIVATION OF CANCER STEM CELLS AND POTENTIATE CYTOTOXIC ANTI-TUMOR DRUG SUBSTANCES | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2016-07-28 | — | — | US | disclosed |
| US-9220695-B2 | Polyenolic zinc-binding agents (pezbins) actively promote inactivation of cancer stem cells and potentiate cytotoxic anti-tumor drug substances | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2015-12-29 | — | — | US | disclosed |
| US-9187406-B2 | Curcumin analogues as zinc chelators and their uses | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2015-11-17 | — | — | US | disclosed |
| US-20150150834-A1 | POLYENOLIC ZINC-BINDING AGENTS (PEZBINS) ACTIVELY PROMOTE INACTIVATION OF CANCER STEM CELLS AND POTENTIATE CYTOTOXIC ANTI-TUMOR DRUG SUBSTANCES | CHEM-MASTER INTERNATIONAL, INC. (US) | 2015-06-04 | — | — | US | disclosed |
| US-20150073021-A1 | CHEMICALLY MODIFIED CURCUMINS AS INHIBITORS OF ANTHRAX LETHAL FACTOR | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2015-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160213638-A1 | POLYENOLIC ZINC-BINDING AGENTS (PEZBINS) ACTIVELY PROMOTE INACTIVATION OF CANCER STEM CELLS AND POTENTIATE CYTOTOXIC ANTI-TUMOR DRUG SUBSTANCES | BAZ2B, CEBPZ, BAZ2A | BACE1 3979/4885MAPT 4394/4885APP 4374/4885 |
| US-20150073021-A1 | CHEMICALLY MODIFIED CURCUMINS AS INHIBITORS OF ANTHRAX LETHAL FACTOR | ANTXR2, APAF1, LITAF | BACE1 1948/4885MAPT 3945/4885APP 569/4885 |
| US-20150150834-A1 | POLYENOLIC ZINC-BINDING AGENTS (PEZBINS) ACTIVELY PROMOTE INACTIVATION OF CANCER STEM CELLS AND POTENTIATE CYTOTOXIC ANTI-TUMOR DRUG SUBSTANCES | BAZ2B, CEBPZ, BAZ2A | BACE1 3979/4885MAPT 4394/4885APP 4374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.